CRIS
Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1
Browse
4 results
Search Results
Now showing 1 - 4 of 4
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Modifier gene identification reveals therapeutic pathways for adult and childhood dementias(Springer Science and Business Media LLC, 2026-02-16) ;Benjamín Szenfeld ;Macarena Las Heras ;Juan Carlos Rubilar ;Leah SkuraJorge Olivares2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genomic variation in Saccharomyces cerevisiae influences paraquat response through differential oxidative stress and vacuolar adaptations(Elsevier BV, 2025-11) ;Juan Carlos Rubilar ;Benjamín Szenfeld ;Francisco A. Cubillos1 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genomic modifiers of neurological resilience in a Niemann‐Pick C family(Wiley, 2025-06-12) ;Macarena Las Heras ;Benjamín Szenfeld ;Valeria Olguín ;Juan Carlos RubilarNiemann-Pick type C (NPC) disease, caused by NPC1 or NPC2 variants, disrupts cholesterol and glycolipid trafficking, leading to diverse clinical manifestations. To understand the genetic basis of neurological resilience, we analyzed an NPC family with variable phenotypes, identifying loss-of-function variants in CCDC115, SLC4A5, DEPDC5, ETFDH, SNRNP200, and DOCK1 that co-segregated with milder neurological involvement. Using yeast models, we successfully predicted NPC-like severity based on orthologous gene variants. RNA-seq revealed a positive correlation between mitochondrial transcripts and cellular fitness. Modeling NPC in yeast lacking the SLC4A5 ortholog, bor1, enhanced cellular fitness, improved mitochondrial function, and reduced sterol accumulation. Our findings identify potential modifiers and biomarkers of NPC severity, highlighting mitochondrial pathways and SLC4A5 as a therapeutic target.6 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Understanding the phenotypic variability in Niemann-Pick disease type C (NPC): a need for precision medicine(2023) ;Macarena Las Heras ;Benjamín Szenfeld ;Rami A. Ballout ;Emanuele BurattiSilvana Zanlungo<jats:title>Abstract</jats:title><jats:p>Niemann-Pick type C (NPC) disease is a lysosomal storage disease (LSD) characterized by the buildup of endo-lysosomal cholesterol and glycosphingolipids due to loss of function mutations in the <jats:italic>NPC1</jats:italic> and <jats:italic>NPC2</jats:italic> genes. NPC patients can present with a broad phenotypic spectrum, with differences at the age of onset, rate of progression, severity, organs involved, effects on the central nervous system, and even response to pharmacological treatments. This article reviews the phenotypic variation of NPC and discusses its possible causes, such as the remaining function of the defective protein, modifier genes, sex, environmental cues, and splicing factors, among others. We propose that these factors should be considered when designing or repurposing treatments for this disease. Despite its seeming complexity, this proposition is not far-fetched, considering the expanding interest in precision medicine and easier access to multi-omics technologies.</jats:p>Scopus© Citations 7 2